Thomas Kipps

InstitutionUniversity of California San Diego
Address9500 Gilman Drive #0820
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Thomas Kipps, MD, PhD, is Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, and Deputy Director of Research Operations at the UC San Diego Moores Cancer Center. He received his Ph.D. in Immunology and M.D. from Harvard University and had his residency and fellowship training in Internal Medicine, Hematology, and Genetics at Stanford University.

    Dr. Kipps has a national and international reputation for his work in cancer research, immunology, and gene therapy. He has been a leader in the field for many years, and has helped to develop standardized treatment protocols. He is the author of more than 300 publications and is the PI on several peer-reviewed grants, including an award from NCI/NIH to fund the Chronic Lymphocytic Leukemia Research Consortium (CRC). The CRC involves collaboration with eight other Cancer Centers around the United States and the UK. Dr. Kipps is also the Director of the Blood Cancer Research Fund at the UC San Diego Moores Cancer Center. The Blood Cancer Research Fund concentrates on developing cures for all types of blood related cancers, specifically Chronic Lymphocytic Leukemia (CLL).

    Dr. Kipps has over 20 years’ experience in combining research and clinical care responsibilities. As deputy director of research operations, Dr. Kipps is working to further integrate basic and translational research investigators at the Moores Cancer Center with clinical investigators, epidemiologists, and physicians offering state-of-the art therapies for patients with various forms of cancer.

    Research Interests
    A major focus of Dr. Kipps’ research is the immunobiology and genetics of human B-cell malignancies, with emphasis on chronic lymphocytic leukemia (CLL). Dr. Kipps’ work has provided insight into the ontogeny of B cells that are subject to leukemia transformation and defined the highly restricted nature of the immunoglobulins expressed in this disease. In addition, he has defined genetic factors that contribute to the development and progression of this disease, identified biochemical pathways that enhance the growth or survival of leukemia B cells, identified means with which to elicit host anti-leukemia immune responses through vaccines generated via gene transfer, and identified promising new drugs and biologic agents that have activity in the treatment of this disease. He has made seminal observations on how the microenvironment can promote survival of CLL cells and defined strategies for mitigating the protective effects of the microenvironment on CLL cells survival in vivo. He has instigated and enabled work on selected leukemia cell samples of patients with sporadic or familial CLL that led to discovery of the role played by microRNA and ultraconserved, non-coding RNAs in the pathogenesis or progression of CLL in collaborations with the laboratory of Dr. Carlo Croce of the CLL Research Consortium (CRC). In other collaborations initiated through the CRC, Dr. Kipps also contributed to work on the epigenetic factors that contribute to pathogenesis in CLL.

    The study on CLL cells serially collected from patients at time points before therapy, during therapy, or after relapse from therapy allows for investigation of the genetic and biologic features associated with tumor progression, therapeutic response, or resistance to therapy. Discovery of features that distinguish CLL from their normal cell counterparts has helped identify new targets for therapy and/or define surrogate markers associated with more rapid rates of cancer progression or resistance to standard therapy. These studies are integrated with a clinical investigative program that attracts patients seeking improved modalities of treatment for CLL. From this, Dr. Kipps has identified molecular markers that can segregate patients into subgroups that have different risks for disease-progression or different probabilities of response to conventional treatment. This also has allowed for testing the safety and relative efficacy of novel agents developed for treatment of all patients with CLL or subgroups of patients hypothesized to have the best potential response to novel forms of therapy.

    Most recently, Dr. Kipps has discovered that the embryonic antigen ROR1 is expressed on CLL. ROR1 an embryonic type I membrane receptor tyrosine kinase-like surface protein. ROR1 was not expressed on normal, healthy adult tissues, but was found on the leukemia cells of virtually all cases of CLL and on the neoplastic cells of many patients with solid tumors. His work has demonstrated that patients immunized with autologous CLL cells transfected to express the CD40-ligand (CD154) can generate antibodies that are specific for this type I tyrosine kinase that apparently can block its capacity to function as a survival receptor for wnt5a. This work potentially could lead to development of novel vaccines for patients with this disease. Currently, Dr. Kipps is collaborating with other investigators at the UC San Diego Moores Cancer Center on developing monoclonal and recombinant antibodies specific for ROR1 and have identified one that can interfere with ROR1 signaling. The California Institute of Regenerative Medicine (CIRM) is funding this work.

    Another project undertaken in the Kipps’ lab is to define the nature of immunoglobulin gene expression in normal and neoplastic B cells and to examine the relationship between B-cell receptor signaling events and mechanisms governing the pathogenesis and/or progression of CLL. In addition he is investigating the role of the microenvironment in support both normal and neoplastic B cell survival. In addition to his laboratory research, Dr. Kipps is actively involved in clinical research; having developed and/or conducted several phase I and phase II clinical trials.

    Collapse Research 
    Collapse Research Activities and Funding
    Lenalidomide Treatment and the Chronic Lymphocytic Leukemia Microenvironment
    NIH/NCI R21CA135681Mar 1, 2009 - Feb 28, 2011
    Role: Principal Investigator
    Center of Nanotechnology for Treatment, Understanding, *
    NIH/NCI U54CA119335Sep 30, 2005 - Dec 31, 2011
    Role: Co-Investigator
    Chronic Lymphocytic Leukemia Research Consortium
    NIH/NCI P01CA081534May 1, 1999 - Aug 31, 2017
    Role: Principal Investigator
    NIH/NCI P20CA081534May 1, 1999 - Apr 30, 2000
    Role: Principal Investigator
    NIH/NIAMS P50AR044850Sep 28, 1998 - Aug 31, 2004
    Role: Co-Investigator
    NIH/NCI R01CA066000Sep 1, 1995 - Jun 30, 2003
    Role: Principal Investigator
    NIH/NCI R01CA065408Jul 25, 1994 - Jun 30, 1998
    Role: Principal Investigator
    NIH/NCI R01CA057868Aug 25, 1992 - Jul 31, 1994
    Role: Principal Investigator
    NIH/NCI R01CA055513Jul 16, 1991 - Jun 30, 1994
    Role: Principal Investigator
    NIH/NCI R01CA054755Mar 14, 1991 - Feb 28, 1995
    Role: Principal Investigator
    Antibody V Gene Expression B Cell Lymphocytic Leukemia
    NIH/NCI R37CA049870May 1, 1989 - Jul 31, 2014
    Role: Principal Investigator
    NIH/NCI R01CA049870May 1, 1989 - Apr 30, 1994
    Role: Principal Investigator
    NIH/NCRR S10RR004051Apr 18, 1988 - Apr 17, 1990
    Role: Principal Investigator
    NIH P60AR033489Feb 1, 1987 - Jun 30, 1990
    Role: Co-Investigator
    NIH/NIAMS R29AR038475Aug 1, 1986 - Jul 31, 1992
    Role: Principal Investigator
    NIH/NIA R01AG004100Jul 1, 1983 - Aug 31, 1996
    Role: Principal Investigator
    NIH/NIA R55AG004100Jul 1, 1983 - Aug 31, 1992
    Role: Principal Investigator
    Specialized Cancer Center Support Grant
    NIH/NCI P30CA023100Apr 1, 1978 - Apr 30, 2019
    Role: Principal Investigator
    NIH M01RR000833Dec 1, 1977 - Sep 30, 2005
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000827Mar 1, 1974 - Nov 30, 2010
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps T, Ghia P. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 Jun 07. PMID: 29880603.
      View in: PubMed
    2. Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps T. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018 Jun 01; 22(6):951-959.e3. PMID: 29859176.
      View in: PubMed
    3. Yu J, Chen Y, Chen L, Zhang L, Rassenti LZ, Widhopf GF, Kipps T. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget. 2018 May 15; 9(37):24731-24736. PMID: 29872501.
      View in: PubMed
    4. Hasan MK, Yu J, Widhopf GF, Rassenti LZ, Chen L, Shen Z, Briggs SP, Neuberg DS, Kipps T. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018 Apr 20. PMID: 29678828.
      View in: PubMed
    5. Seymour JF, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018 03 22; 378(12):1107-1120. PMID: 29562156.
      View in: PubMed
    6. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps T. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood. 2018 Mar 14. PMID: 29540348.
      View in: PubMed
    7. O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps T, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol. 2018 Feb 22. PMID: 29470582.
      View in: PubMed
    8. Gonzalez VD, Samusik N, Chen TJ, Savig ES, Aghaeepour N, Quigley DA, Huang YW, Giangarrà V, Borowsky AD, Hubbard NE, Chen SY, Han G, Ashworth A, Kipps T, Berek JS, Nolan GP, Fantl WJ. Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. Cell Rep. 2018 Feb 13; 22(7):1875-1888. PMID: 29444438.
      View in: PubMed
    9. Mato A, Nabhan C, Kay NE, Lamanna N, Kipps T, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk. 2018 Feb; 18(2):114-124.e2. PMID: 29352719.
      View in: PubMed
    10. Coutre S, Tedeschi A, Robak T, Barr PM, Owen C, Bairey O, Burger J, Zhou C, Styles L, James DF, Kipps T. Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2017 Nov 23. PMID: 29170253.
      View in: PubMed
    11. Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps T, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Nov; 15(11):1414-1427. PMID: 29118233.
      View in: PubMed
    12. Zhou Y, Kipps T, Zhang S. Corrigendum to "Wnt5a Signaling in Normal and Cancer Stem Cells". Stem Cells Int. 2017; 2017:3467360. PMID: 29098008.
      View in: PubMed
    13. Rassenti LZ, Balatti V, Ghia EM, Palamarchuk A, Tomasello L, Fadda P, Pekarsky Y, Widhopf GF, Kipps T, Croce CM. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2017 Oct 03; 114(40):10731-10736. PMID: 28923920.
      View in: PubMed
    14. Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps T, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 Oct; 102(10):1796-1805. PMID: 28751558.
      View in: PubMed
    15. Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY, Amine AA, Rassenti LZ, Zhang C, Liu SH, Smeal T, Fantin VR, Kipps T, Pernasetti F, Castro JE. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol. 2017 May 19; 10(1):112. PMID: 28526063.
      View in: PubMed
    16. Miller CR, Ruppert AS, Fobare S, Chen TL, Liu C, Lehman A, Blachly JS, Zhang X, Lucas DM, Grever MR, Tallman MS, Flinn IW, Rassenti LZ, Kipps T, Sampath D, Coombes KR, Hertlein EK. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget. 2017 Apr 18; 8(16):25942-25954. PMID: 28412730.
      View in: PubMed
    17. Zhou Y, Kipps T, Zhang S. Wnt5a Signaling in Normal and Cancer Stem Cells. Stem Cells Int. 2017; 2017:5295286. PMID: 28491097.
      View in: PubMed
    18. Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps T, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017 07; 178(2):286-291. PMID: 28397242.
      View in: PubMed
    19. Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps T, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Böttcher S, Ritgen M, Goede V, Mobasher M, Hallek M. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 05 11; 129(19):2702-2705. PMID: 28325865.
      View in: PubMed
    20. Kipps T, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 Feb 09; 3:17008. PMID: 28179635.
      View in: PubMed
    21. Kipps T, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 01 19; 3:16096. PMID: 28102226.
      View in: PubMed
    22. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps T, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10; 35(8):826-833. PMID: 28095146.
      View in: PubMed
    23. Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps T, Roberts AW. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb; 18(2):230-240. PMID: 28089635.
      View in: PubMed
    24. Barile E, Marconi GD, De SK, Baggio C, Gambini L, Salem AF, Kashyap MK, Castro JE, Kipps T, Pellecchia M. hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents. ACS Chem Biol. 2017 Feb 17; 12(2):444-455. PMID: 28026162.
      View in: PubMed
    25. Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps T, Grinblatt DL, Flinn IW, Kozloff MF, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP. Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016 Dec; 175(5):892-903. PMID: 27861736.
      View in: PubMed
    26. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps T. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 12 22; 128(25):2931-2940. PMID: 27815263.
      View in: PubMed
    27. Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, Cibulskis CL, Zhang W, Rassenti LZ, Ghia EM, Kipps T, Fernandes S, Bloch DB, Kotliar D, Landau DA, Shukla SA, Aster JC, Reed R, DeLuca DS, Brown JR, Neuberg D, Getz G, Livak KJ, Meyerson MM, Kharchenko PV, Wu CJ. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763. PMID: 27818134.
      View in: PubMed
    28. Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol. 2018 02; 180(4):597-600. PMID: 27766619.
      View in: PubMed
    29. Choi MY, Kipps T. How Do Targeted Therapies Change the Management of Indolent Lymphomas? Oncology (Williston Park). 2016 09 15; 30(9):859-60. PMID: 27633418.
      View in: PubMed
    30. Sattari A, Siddiqui H, Moshiri F, Ngankeu A, Nakamura T, Kipps T, Croce CM. Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias. Oncotarget. 2016 08 23; 7(34):54174-54182. PMID: 27527866.
      View in: PubMed
    31. Castro JE, Kipps T. Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more. Best Pract Res Clin Haematol. 2016 Mar; 29(1):15-29. PMID: 27742068.
      View in: PubMed
    32. Kumar D, Kashyap MK, La Clair JJ, Villa R, Spaanderman I, Chien S, Rassenti LZ, Kipps T, Burkart MD, Castro JE. Selectivity in Small Molecule Splicing Modulation. ACS Chem Biol. 2016 10 21; 11(10):2716-2723. PMID: 27499047.
      View in: PubMed
    33. Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps T, Brown JR, Mraz M. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 09 22; 128(12):1609-13. PMID: 27480113.
      View in: PubMed
    34. Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Ther. 2016 08; 15(8):1781-91. PMID: 27413114.
      View in: PubMed
    35. Jewell RC, Kipps T, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma. 2017 02; 58(2):348-356. PMID: 27389174.
      View in: PubMed
    36. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps T, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203. PMID: 27247136; PMCID: PMC4946200 [Available on 07/14/17].
    37. Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps T. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2016 07; 101(7):e295-8. PMID: 27151992; PMCID: PMC5004476.
    38. Baggio C, Barile E, Di Sorbo G, Kipps T, Pellecchia M. The Cell Surface Receptor CD44: NMR-Based Characterization of Putative Ligands. ChemMedChem. 2016 05 19; 11(10):1097-106. PMID: 27144715.
      View in: PubMed
    39. Burger JA, Styles L, Kipps T. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med. 2016 04 21; 374(16):1594-5. PMID: 27096594.
      View in: PubMed
    40. Pekarsky Y, Balatti V, Palamarchuk A, Rizzotto L, Veneziano D, Nigita G, Rassenti LZ, Pass HI, Kipps T, Liu CG, Croce CM. Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. Proc Natl Acad Sci U S A. 2016 May 03; 113(18):5071-6. PMID: 27071132; PMCID: PMC4983805 [Available on 11/03/16].
    41. Van Dyke DL, Werner L, Rassenti LZ, Neuberg D, Ghia E, Heerema NA, Dal Cin P, Dell Aquila M, Sreekantaiah C, Greaves AW, Kipps T, Kay NE. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol. 2016 Apr; 173(1):105-13. PMID: 26848054; PMCID: PMC4963001.
    42. Yu J, Chen L, Cui B, Widhopf GF, Shen Z, Wu R, Zhang L, Zhang S, Briggs SP, Kipps T. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016 Feb; 126(2):585-98. PMID: 26690702; PMCID: PMC4731190.
    43. Kashyap MK, Kumar D, Jones H, Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR, Sabbatini P, Cohen LJ, Shelat SG, Rassenti LZ, Kipps T, Cardarelli PM, Castro JE. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19; 7(3):2809-22. PMID: 26646452; PMCID: PMC4823073.
    44. Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps T, Mertens D, Zapatka M, Lichter P, Döhner H, Küppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016 Mar; 48(3):253-64. PMID: 26780610; PMCID: PMC4963005.
    45. Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps T, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016; 57(6):1291-9. PMID: 26763349.
      View in: PubMed
    46. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps T. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17; 373(25):2425-37. PMID: 26639149; PMCID: PMC4722809.
    47. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps T, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):311-22. PMID: 26639348.
      View in: PubMed
    48. Byrd JC, Flynn JM, Kipps T, Boxer M, Kolibaba KS, Carlile DJ, Fingerle-Rowson G, Tyson N, Hirata J, Sharman JP. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016 Jan 07; 127(1):79-86. PMID: 26472752; PMCID: PMC4705612.
    49. O'Brien SM, Lamanna N, Kipps T, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17; 126(25):2686-94. PMID: 26472751; PMCID: PMC4732760.
    50. Tili E, Chiabai M, Palmieri D, Brown M, Cui R, Fernandes C, Richmond T, Kim T, Sheetz T, Sun HL, Lagana A, Veneziano D, Volinia S, Rassenti L, Kipps T, Awad H, Michaille JJ, Croce CM. Quaking and miR-155 interactions in inflammation and leukemogenesis. Oncotarget. 2015 Sep 22; 6(28):24599-610. PMID: 26337206; PMCID: PMC4694781.
    51. Patton WN, Lindeman R, Butler AC, Kipps T, Jewell RC, Laubscher KH, Zhou YY, Lewis E, Sedoti D, Witman P, Fang L, Chan G. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(10):2819-25. PMID: 25721750; PMCID: PMC4654681.
    52. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps T, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600.
      View in: PubMed
    53. Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, Widhopf GF, Hurton LV, Thokala R, Singh H, Olivares S, Champlin RE, Wierda WG, Kipps T, Cooper LJ. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One. 2015; 10(6):e0128151. PMID: 26030772; PMCID: PMC4451012.
    54. Choi MY, Widhopf GF, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C, Kipps T. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S167-9. PMID: 26297272; PMCID: PMC4548279.
    55. Kipps T, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, Yalamanchili S, Chai A, Sahasranaman S, Punnoose E, Hurst D, Pylypenko H. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(10):2826-33. PMID: 25797560; PMCID: PMC4643417.
    56. Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps T, Dick JE, Stover DR. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Mol Cancer Ther. 2015 Jul; 14(7):1650-60. PMID: 25934707; PMCID: PMC4557793.
    57. Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D'Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps T, Kay NE, Keating M, Calin GA. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine. 2015 Jun; 2(6):572-82. PMID: 26288818; PMCID: PMC4535165.
    58. Smith EN, Ghia EM, DeBoever CM, Rassenti LZ, Jepsen K, Yoon KA, Matsui H, Rozenzhak S, Alakus H, Shepard PJ, Dai Y, Khosroheidari M, Bina M, Gunderson KL, Messer K, Muthuswamy L, Hudson TJ, Harismendy O, Barrett CL, Jamieson CH, Carson DA, Kipps T, Frazer KA. Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. Blood Cancer J. 2015 Apr 10; 5:e303. PMID: 25860294; PMCID: PMC4450323.
    59. Kashyap MK, Kumar D, Villa R, La Clair JJ, Benner C, Sasik R, Jones H, Ghia EM, Rassenti LZ, Kipps T, Burkart MD, Castro JE. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. Haematologica. 2015 Jul; 100(7):945-54. PMID: 25862704; PMCID: PMC4486229.
    60. Blachly JS, Ruppert AS, Zhao W, Long S, Flynn J, Flinn I, Jones J, Maddocks K, Andritsos L, Ghia EM, Rassenti LZ, Kipps T, de la Chapelle A, Byrd JC. Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015 Apr 07; 112(14):4322-7. PMID: 25787252; PMCID: PMC4394264.
    61. DeBoever C, Ghia EM, Shepard PJ, Rassenti L, Barrett CL, Jepsen K, Jamieson CH, Carson D, Kipps T, Frazer KA. Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers. PLoS Comput Biol. 2015 Mar; 11(3):e1004105. PMID: 25768983; PMCID: PMC4358997.
    62. Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps T. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015 Apr 30; 125(18):2779-85. PMID: 25769620; PMCID: PMC4416529.
    63. Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps T, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015 Aug; 100(8):e311-4. PMID: 25769539; PMCID: PMC5004432.
    64. Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps T, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May; 39(5):495-500. PMID: 25804339; PMCID: PMC4557608.
    65. Balatti V, Rizzotto L, Miller C, Palamarchuk A, Fadda P, Pandolfo R, Rassenti LZ, Hertlein E, Ruppert AS, Lozanski A, Lozanski G, Kipps T, Byrd JC, Croce CM, Pekarsky Y. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015 Feb 17; 112(7):2169-74. PMID: 25646413; PMCID: PMC4343115.
    66. Kämpjärvi K, Järvinen TM, Heikkinen T, Ruppert AS, Senter L, Hoag KW, Dufva O, Kontro M, Rassenti L, Hertlein E, Kipps T, Porkka K, Byrd JC, de la Chapelle A, Vahteristo P. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget. 2015 Jan 30; 6(3):1884-8. PMID: 25595892; PMCID: PMC4359339.
    67. Urquiza M, Melo-Cardenas J, Aguillon R, Kipps T, Castro JE. Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan; 26(1):14-25. PMID: 25382101; PMCID: PMC4303189.
    68. Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Jun; 56(6):1878-80. PMID: 25311497; PMCID: PMC4547465.
    69. Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF, Zhang Z, Wu CC, Chen L, Wu R, Schwab R, Carson DA, Kipps T. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A. 2014 Dec 02; 111(48):17266-71. PMID: 25411317; PMCID: PMC4260559.
    70. Castro JE, Choi MY, Carvajal T, Almahasnah E, Chang J, James DF, Kipps T. Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. Blood Cancer J. 2014 Nov 14; 4:e258. PMID: 25397619; PMCID: PMC4571984.
    71. Smith EN, Jepsen K, Khosroheidari M, Rassenti LZ, D'Antonio M, Ghia EM, Carson DA, Jamieson CH, Kipps T, Frazer KA. Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments. Genome Biol. 2014 Aug 07; 15(8):420. PMID: 25103687; PMCID: PMC4165357.
    72. Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez-Girona A, Messmer D, Kipps T. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014 Sep 04; 124(10):1637-44. PMID: 24990888; PMCID: PMC4155272.
    73. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, Ghia EM, Zhang L, Bao L, Rassenti LZ, Messer K, Calin GA, Croce CM, Kipps T. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014 Jul 24; 124(4):546-54. PMID: 24914134; PMCID: PMC4110661.
    74. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps T, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17; 371(3):213-23. PMID: 24881631; PMCID: PMC4134521.
    75. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps T. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014 Jul 01; 32(19):2067-73. PMID: 24868031; PMCID: PMC4067945.
    76. Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps T, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 03; 124(1):42-8. PMID: 24868078; PMCID: PMC4125353.
    77. Glibert P, Vossaert L, Van Steendam K, Lambrecht S, Van Nieuwerburgh F, Offner F, Kipps T, Dhaenens M, Deforce D. Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line. Int J Mol Sci. 2014 May 27; 15(6):9407-21. PMID: 24871368; PMCID: PMC4100102.
    78. Acunzo M, Romano G, Wernicke D, Balatti V, Rassenti LZ, dell'Aquila M, Kipps T, Pekarsky Y, Croce CM. Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. Blood. 2014 Jul 10; 124(2):259-62. PMID: 24855209; PMCID: PMC4093682.
    79. Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM, Ramsay AG, Rassenti LZ, Kipps T, Gribben JG. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood. 2014 Jun 26; 123(26):4101-10. PMID: 24829201; PMCID: PMC4073326.
    80. Sonnenberg A, Marciniak JY, Skowronski EA, Manouchehri S, Rassenti L, Ghia EM, Widhopf GF, Kipps T, Heller MJ. Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. Electrophoresis. 2014 Jul; 35(12-13):1828-36. PMID: 24723219; PMCID: PMC4214757.
    81. Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps T. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014 Jul 03; 124(1):84-95. PMID: 24787006; PMCID: PMC4125356.
    82. Veronese A, Pepe F, Chiacchia J, Pagotto S, Lanuti P, Veschi S, Di Marco M, D'Argenio A, Innocenti I, Vannata B, Autore F, Marchisio M, Wernicke D, Verginelli F, Leone G, Rassenti LZ, Kipps T, Mariani-Costantini R, Laurenti L, Croce CM, Visone R. Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia. 2015 Jan; 29(1):86-95. PMID: 24732594; PMCID: PMC4198514.
    83. Burt JS, Kipps T, Matthews JR. Repetition in visual word identification: benefits and costs. Q J Exp Psychol (Hove). 2014 Oct; 67(10):1986-2009. PMID: 25248100.
      View in: PubMed
    84. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW, McLeod JL, Doedens M, Medeiros JJ, Marke R, Kim HJ, Lee K, McPherson JD, Hudson TJ. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014 Feb 20; 506(7488):328-33. PMID: 24522528; PMCID: PMC4991939.
    85. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps T, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13; 370(11):997-1007. PMID: 24450857; PMCID: PMC4161365.
    86. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps T, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014 Mar 20; 123(12):1810-7. PMID: 24415539; PMCID: PMC3962160.
    87. Widhopf GF, Cui B, Ghia EM, Chen L, Messer K, Shen Z, Briggs SP, Croce CM, Kipps T. ROR1 can interact with TCL1 and enhance leukemogenesis in Eµ-TCL1 transgenic mice. Proc Natl Acad Sci U S A. 2014 Jan 14; 111(2):793-8. PMID: 24379361; PMCID: PMC3896194.
    88. Oakes CC, Claus R, Gu L, Assenov Y, Hüllein J, Zucknick M, Bieg M, Brocks D, Bogatyrova O, Schmidt CR, Rassenti L, Kipps T, Mertens D, Lichter P, Döhner H, Stilgenbauer S, Byrd JC, Zenz T, Plass C. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014 Mar; 4(3):348-61. PMID: 24356097; PMCID: PMC4134522.
    89. Sonnenberg A, Marciniak JY, Rassenti L, Ghia EM, Skowronski EA, Manouchehri S, McCanna J, Widhopf GF, Kipps T, Heller MJ. Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin Chem. 2014 Mar; 60(3):500-9. PMID: 24270796; PMCID: PMC4114224.
    90. Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JE, Cameron K, Hahne M, Pals S, Slinger E, Kipps T, van Oers MH, Eldering E, Medema JP, Kater AP. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. Blood. 2013 Dec 05; 122(24):3960-3. PMID: 24100449; PMCID: PMC4123411.
    91. Zhang S, Kipps T. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014; 9:103-18. PMID: 23987584; PMCID: PMC4144790.
    92. Villa R, Kashyap MK, Kumar D, Kipps T, Castro JE, La Clair JJ, Burkart MD. Stabilized cyclopropane analogs of the splicing inhibitor FD-895. J Med Chem. 2013 Sep 12; 56(17):6576-82. PMID: 23919277; PMCID: PMC3809018.
    93. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps T, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12; 122(11):1891-9. PMID: 23821659; PMCID: PMC3779381.
    94. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps T, Jones JA, Badoux X, Kantarjian H, Keating MJ. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):568-74. PMID: 23810245; PMCID: PMC4180513.
    95. Que X, Widhopf GF, Amir S, Hartvigsen K, Hansen LF, Woelkers D, Tsimikas S, Binder CJ, Kipps T, Witztum JL. IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. PLoS One. 2013; 8(6):e65203. PMID: 23840319; PMCID: PMC3688726.
    96. Cui B, Zhang S, Chen L, Yu J, Widhopf GF, Fecteau JF, Rassenti LZ, Kipps T. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013 Jun 15; 73(12):3649-60. PMID: 23771907; PMCID: PMC3832210.
    97. Mraz M, Kipps T. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Aug; 54(8):1836-9. PMID: 23597135; PMCID: PMC4144718.
    98. Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps T, Neuberg D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70. PMID: 23645694; PMCID: PMC3669454.
    99. Sonnenberg A, Marciniak JY, McCanna J, Krishnan R, Rassenti L, Kipps T, Heller MJ. Dielectrophoretic isolation and detection of cfc-DNA nanoparticulate biomarkers and virus from blood. Electrophoresis. 2013 Apr; 34(7):1076-84. PMID: 23436471; PMCID: PMC4517469.
    100. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S, Kipps T. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6127-32. PMID: 23530247; PMCID: PMC3625269.
    101. Schwaederlé M, Ghia E, Rassenti LZ, Obara M, Dell'Aquila ML, Fecteau JF, Kipps T. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia. 2013 Apr; 27(5):1214-7. PMID: 23337928; PMCID: PMC3650490.
    102. Fecteau JF, Messmer D, Zhang S, Cui B, Chen L, Kipps T. Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood. 2013 Feb 07; 121(6):971-4. PMID: 23255557; PMCID: PMC3567343.
    103. Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun HL, Gasparini P, Efanov A, Peng Y, Zanesi N, Shuaib MA, Rassenti LZ, Kipps T, Li C, Aqeilan RI, Lesinski GB, Trapasso F, Croce CM. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood. 2013 Jan 10; 121(2):351-9. PMID: 23160471; PMCID: PMC3544116.
    104. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, Wu R, Kipps T. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012 Dec; 181(6):1903-10. PMID: 23041612; PMCID: PMC3509760.
    105. Choi MY, Kipps T. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 2012 Sep-Oct; 18(5):404-10. PMID: 23006944; PMCID: PMC3461329.
    106. Balatti V, Lerner S, Rizzotto L, Rassenti LZ, Bottoni A, Palamarchuk A, Cascione L, Alder H, Keating MJ, Kipps T, Pekarsky Y, Croce CM. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia. 2013 Mar; 27(3):740-3. PMID: 22902365; PMCID: PMC3733494.
    107. Wu RP, Li H, Rassenti LZ, Hayashi T, Wu CN, Kipps T, Messer K, Carson DA. Increased aldehyde dehydrogenase activity in high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Feb; 54(2):400-2. PMID: 22784365; PMCID: PMC3821178.
    108. Chuang HY, Rassenti L, Salcedo M, Licon K, Kohlmann A, Haferlach T, Foà R, Ideker T, Kipps T. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood. 2012 Sep 27; 120(13):2639-49. PMID: 22837534; PMCID: PMC3460686.
    109. Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, Wiestner A, Kipps T. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10; 30(23):2820-2. PMID: 22778323; PMCID: PMC3410400.
    110. Coombs CC, Rassenti LZ, Falchi L, Slager SL, Strom SS, Ferrajoli A, Weinberg JB, Kipps T, Lanasa MC. Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood. 2012 Aug 23; 120(8):1687-90. PMID: 22745306; PMCID: PMC3429309.
    111. Tili E, Michaille JJ, Luo Z, Volinia S, Rassenti LZ, Kipps T, Croce CM. The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood. 2012 Sep 27; 120(13):2631-8. PMID: 22723551; PMCID: PMC3460685.
    112. Byrd JC, Kipps T, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien S. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Nov; 53(11):2136-42. PMID: 22475052.
      View in: PubMed
    113. Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps T, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JC. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol. 2012 Jul 10; 30(20):2483-91. PMID: 22564988; PMCID: PMC3397783.
    114. Castro JE, Melo-Cardenas J, Urquiza M, Barajas-Gamboa JS, Pakbaz RS, Kipps T. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res. 2012 Jun 15; 72(12):2937-48. PMID: 22505652; PMCID: PMC4114227.
    115. Castro JE, Diaz-Perez JA, Barajas-Gamboa JS, Horton JM, Weidner N, Kipps T. Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab. Leuk Lymphoma. 2012 Sep; 53(9):1835-8. PMID: 22335532; PMCID: PMC4557775.
    116. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps T. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012; 7(3):e31127. PMID: 22403610; PMCID: PMC3293865.
    117. Fecteau JF, Bharati IS, O'Hayre M, Handel TM, Kipps T, Messmer D. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med. 2012 Feb 10; 18:19-28. PMID: 21979753; PMCID: PMC3269641.
    118. Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M, Balatti V, Bottoni A, Nazaryan N, Alder H, Rassenti L, Kipps T, Freitas M, Croce CM, Pekarsky Y. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2012 Feb 14; 109(7):2555-60. PMID: 22308499; PMCID: PMC3289317.
    119. Steininger C, Widhopf GF, Ghia EM, Morello CS, Vanura K, Sanders R, Spector D, Guiney D, Jäger U, Kipps T. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood. 2012 Mar 08; 119(10):2293-301. PMID: 22234695; PMCID: PMC3311256.
    120. Fecteau JF, Kipps T. Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed). 2012 Jan 01; 4:61-73. PMID: 22202043; PMCID: PMC4114230.
    121. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps T, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012 Feb 10; 30(5):488-96. PMID: 22184378; PMCID: PMC4979082.
    122. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps T, Pekarsky Y, Croce CM. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012 Jan 12; 119(2):329-31. PMID: 22086416; PMCID: PMC3257004.
    123. Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, Leber AS, Kaou M, Zanesi N, Bottoni A, Costinean S, Rassenti LZ, Nakamura T, Kipps T, Aqeilan RI, Pekarsky Y, Trapasso F, Croce CM. Tcl1 interacts with Atm and enhances NF-?B activation in hematologic malignancies. Blood. 2012 Jan 05; 119(1):180-7. PMID: 22065599; PMCID: PMC3251228.
    124. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps T. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res. 2011 Oct; 35(10):1390-4. PMID: 21813176; PMCID: PMC3163753.
    125. Peiró AM, Tang CM, Murray F, Zhang L, Brown LM, Chou D, Rassenti L, Kipps TJ, Kipps T, Insel PA. Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease. J Hum Genet. 2011 Sep; 56(9):676-81. PMID: 21796143; PMCID: PMC3833258.
    126. Lu D, Choi MY, Yu J, Castro JE, Kipps T, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 09; 108(32):13253-7. PMID: 21788521; PMCID: PMC3156152.
    127. Havelange V, Pekarsky Y, Nakamura T, Palamarchuk A, Alder H, Rassenti L, Kipps T, Croce CM. IRF4 mutations in chronic lymphocytic leukemia. Blood. 2011 Sep 08; 118(10):2827-9. PMID: 21791429; PMCID: PMC3172799.
    128. James DF, Kipps T. Rituximab in chronic lymphocytic leukemia. Adv Ther. 2011 Jul; 28(7):534-54. PMID: 21725721.
      View in: PubMed
    129. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, Volinia S, Taccioli C, Kipps T, Croce CM. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood. 2011 Sep 15; 118(11):3072-9. PMID: 21636858; PMCID: PMC3175784.
    130. Messmer BT, Nour-Omid TS, Ghia E, Sanchez AB, Kipps T. Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia. Leuk Res. 2011 Jul; 35(7):965-7. PMID: 21570119; PMCID: PMC3116639.
    131. Ghia EM, Widhopf GF, Rassenti LZ, Kipps T. Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia. J Immunol. 2011 Jun 01; 186(11):6338-44. PMID: 21525382.
      View in: PubMed
    132. Wierda WG, Kipps T, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011 Jun 16; 117(24):6450-8. PMID: 21498674; PMCID: PMC4916561.
    133. Buhl AM, James DF, Neuberg D, Jain S, Rassenti LZ, Kipps T. Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. Eur J Haematol. 2011 May; 86(5):405-411. PMID: 21323738; PMCID: PMC4114228.
    134. Zhang L, Murray F, Rassenti LZ, Pu M, Kelly C, Kanter JR, Greaves A, Messer K, Kipps T, Insel PA. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer. 2011 Sep 01; 129(5):1162-9. PMID: 21120911; PMCID: PMC3111850.
    135. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell'Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps T, Calin GA, Croce CM. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011 Jan 05; 305(1):59-67. PMID: 21205967; PMCID: PMC3690301.
    136. Heerema NA, Byrd JC, Dal Cin PS, Dell' Aquila ML, Koduru PR, Aviram A, Smoley SA, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps T, Kay NE, Van Dyke DL. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet. 2010 Dec; 203(2):134-40. PMID: 21156225; PMCID: PMC3018693.
    137. Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell' Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps T, Dewald GW. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec; 203(2):141-8. PMID: 21156226; PMCID: PMC3763815.
    138. Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010 Dec; 203(2):161-8. PMID: 21156228; PMCID: PMC3026606.
    139. Sivina M, Hartmann E, Kipps T, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 03; 117(5):1662-9. PMID: 21115978; PMCID: PMC3318778.
    140. Messmer D, Fecteau JF, O'Hayre M, Bharati IS, Handel TM, Kipps T. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood. 2011 Jan 20; 117(3):882-9. PMID: 21079155; PMCID: PMC3035080.
    141. Zhang W, Kater AP, Widhopf GF, Chuang HY, Enzler T, James DF, Poustovoitov M, Tseng PH, Janz S, Hoh C, Herschman H, Karin M, Kipps T. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2010 Nov 02; 107(44):18956-60. PMID: 20956327; PMCID: PMC2973856.
    142. Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps T, Neuberg D, Freedman AS, Lee C, Brown JR. Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol. 2010 Nov; 151(4):336-45. PMID: 20812997; PMCID: PMC3584328.
    143. Wierda WG, Kipps T, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 01; 117(1):116-24. PMID: 20806349; PMCID: PMC4535917.
    144. Chanan-Khan A, Kipps T, Stilgenbauer S. Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse events. Clin Adv Hematol Oncol. 2010 Aug; 8(8):suppl 1-15. PMID: 21192630.
      View in: PubMed
    145. O'Hayre M, Salanga CL, Kipps T, Messmer D, Dorrestein PC, Handel TM. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS One. 2010 Jul 22; 5(7):e11716. PMID: 20661426; PMCID: PMC2908618.
    146. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A. 2010 Jul 06; 107(27):12210-5. PMID: 20566844; PMCID: PMC2901490.
    147. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps T, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010 May; 20(5):589-99. PMID: 20439436; PMCID: PMC2860161.
    148. Du S, Rashidi HH, Le DT, Kipps T, Broome HE, Wang HY. Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol. 2010 Apr 23; 3(4):448-57. PMID: 20490336; PMCID: PMC2872752.
    149. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Béné MC, De Vos J, Hernández JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps T, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foà R. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010 May 20; 28(15):2529-37. PMID: 20406941.
      View in: PubMed
    150. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps T, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010 Aug 12; 116(6):945-52. PMID: 20393129; PMCID: PMC4916575.
    151. Shi R, Re D, Dudl E, Cuddy M, Okolotowicz KJ, Dahl R, Su Y, Hurder A, Kitada S, Peddibhotla S, Roth GP, Smith LH, Kipps T, Cosford N, Cashman J, Reed JC. Chemical biology strategy reveals pathway-selective inhibitor of NF-kappaB activation induced by protein kinase C. ACS Chem Biol. 2010 Mar 19; 5(3):287-99. PMID: 20141195; PMCID: PMC2842467.
    152. Wierda WG, Kipps T, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 01; 28(10):1749-55. PMID: 20194866; PMCID: PMC4979101.
    153. Sanchez AB, Nguyen T, Dema-Ala R, Kummel AC, Kipps T, Messmer BT. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Cancer Chemother Pharmacol. 2010 Oct; 66(5):919-25. PMID: 20087593; PMCID: PMC2921063.
    154. Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood. 2010 May 13; 115(19):3916-22. PMID: 20071661; PMCID: PMC2869560.
    155. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps T, Carson DA. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One. 2009 Dec 14; 4(12):e8294. PMID: 20011538; PMCID: PMC2789382.
    156. Wojcik SE, Rossi S, Shimizu M, Nicoloso MS, Cimmino A, Alder H, Herlea V, Rassenti LZ, Rai KR, Kipps T, Keating MJ, Croce CM, Calin GA. Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis. 2010 Feb; 31(2):208-15. PMID: 19926640; PMCID: PMC2812567.
    157. Byrd JC, Kipps T, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010 Jan 21; 115(3):489-95. PMID: 19843887; PMCID: PMC2810983.
    158. Enzler T, Kater AP, Zhang W, Widhopf GF, Chuang HY, Lee J, Avery E, Croce CM, Karin M, Kipps T. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood. 2009 Nov 12; 114(20):4469-76. PMID: 19755673.
      View in: PubMed
    159. Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, Volinia S, Ferracin M, Palatini J, Balatti V, Alder H, Negrini M, Kipps T, Croce CM. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009 Oct 29; 114(18):3872-9. PMID: 19717645; PMCID: PMC2773482.
    160. Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps T, Hennighausen L, Iwama A, Nakauchi H, Kawakami T. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell. 2009 Aug 04; 16(2):161-71. PMID: 19647226; PMCID: PMC2744338.
    161. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, Kipps T, Croce CM. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008 Dec 16; 105(50):19643-8. PMID: 19064921; PMCID: PMC2604915.
    162. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps T, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009 Apr 02; 113(14):3168-71. PMID: 19050308; PMCID: PMC4916943.
    163. Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, Fenlon M, Rassenti L, Cottam H, Kipps T, Insel PA. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2008 Dec 09; 105(49):19532-7. PMID: 19033455; PMCID: PMC2614795.
    164. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009 Jan 08; 113(2):299-305. PMID: 18931344; PMCID: PMC4968372.
    165. Kohlmann A, Kipps T, Rassenti LZ, Downing JR, Shurtleff SA, Mills KI, Gilkes AF, Hofmann WK, Basso G, Dell'orto MC, Foà R, Chiaretti S, De Vos J, Rauhut S, Papenhausen PR, Hernández JM, Lumbreras E, Yeoh AE, Koay ES, Li R, Liu WM, Williams PM, Wieczorek L, Haferlach T. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br J Haematol. 2008 Sep; 142(5):802-7. PMID: 18573112; PMCID: PMC2654477.
    166. Kipps T. Genomic complexity in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1550. PMID: 18725569.
      View in: PubMed
    167. Messmer BT, Raphael BJ, Aerni SJ, Widhopf GF, Rassenti LZ, Gribben JG, Kay NE, Kipps T. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res. 2009 Mar; 33(3):368-76. PMID: 18640719; PMCID: PMC2692898.
    168. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps T. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1923-30. PMID: 18577710; PMCID: PMC2518894.
    169. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps T, Negrini M, Croce CM. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008 Apr 01; 105(13):5166-71. PMID: 18362358; PMCID: PMC2278188.
    170. Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps T. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May 15; 111(10):5101-8. PMID: 18326815; PMCID: PMC2384137.
    171. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, Widhopf GF, Rassenti LZ, Cantwell MJ, Prussak CE, Carson DA, Kipps T. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3047-52. PMID: 18287027; PMCID: PMC2268582.
    172. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps T. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15; 111(12):5446-56. PMID: 18216293.
      View in: PubMed
    173. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps T, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203. PMID: 18182662.
      View in: PubMed
    174. Nicoloso MS, Kipps T, Croce CM, Calin GA. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol. 2007 Dec; 139(5):709-16. PMID: 18021085.
      View in: PubMed
    175. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, Kipps T. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008 Mar 01; 111(5):2685-92. PMID: 18048647; PMCID: PMC2254551.
    176. Kipps T. Value of computed tomography in the monitoring of patients with chronic lymphocytic leukemia. J Clin Oncol. 2007 Dec 10; 25(35):5556. PMID: 17984183.
      View in: PubMed
    177. Wierda WG, Kipps T. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol. 2007 Sep; 20(3):557-68. PMID: 17707840.
      View in: PubMed
    178. Kipps T. The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007 Sep; 20(3):415-24. PMID: 17707830.
      View in: PubMed
    179. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps T, Negrini M, Croce CM. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007 Sep; 12(3):215-29. PMID: 17785203.
      View in: PubMed
    180. Sellick GS, Goldin LR, Wild RW, Slager SL, Ressenti L, Strom SS, Dyer MJ, Mauro FR, Marti GE, Fuller S, Lyttelton M, Kipps T, Keating MJ, Call TG, Catovsky D, Caporaso N, Houlston RS. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood. 2007 Nov 01; 110(9):3326-33. PMID: 17687107; PMCID: PMC2200912.
    181. Widhopf GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps T. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood. 2008 Mar 15; 111(6):3137-44. PMID: 17675554; PMCID: PMC2265453.
    182. Byrd JC, O'Brien S, Flinn IW, Kipps T, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4448-55. PMID: 17671129.
      View in: PubMed
    183. Kater AP, van Oers MH, Kipps T. Cellular immune therapy for chronic lymphocytic leukemia. Blood. 2007 Oct 15; 110(8):2811-8. PMID: 17638850.
      View in: PubMed
    184. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps T, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007 Jun 01; 129(5):879-90. PMID: 17540169; PMCID: PMC4647864.
    185. Kato K, Chu P, Takahashi S, Hamada H, Kipps T. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Exp Hematol. 2007 Mar; 35(3):434-42. PMID: 17309824.
      View in: PubMed
    186. James DF, Kipps T. Alemtuzumab in chronic lymphocytic leukemia. Future Oncol. 2007 Feb; 3(1):29-42. PMID: 17280499.
      View in: PubMed
    187. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006 Dec 15; 66(24):11590-3. PMID: 17178851.
      View in: PubMed
    188. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, Karin M, Kipps T. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2007 Jan 15; 109(2):703-10. PMID: 16973958; PMCID: PMC1890820.
    189. Rassenti LZ, Kipps T. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2006 Jul 15; 70(4):209-13. PMID: 16906583.
      View in: PubMed
    190. Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps T. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood. 2006 Nov 15; 108(10):3450-7. PMID: 16741250; PMCID: PMC1895435.
    191. Messmer D, Kipps T. CD154 gene therapy for human B-cell malignancies. Ann N Y Acad Sci. 2005 Dec; 1062:51-60. PMID: 16461788.
      View in: PubMed
    192. Burger JA, Kipps T. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006 Mar 01; 107(5):1761-7. PMID: 16269611.
      View in: PubMed
    193. Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005 Nov; 29(11):1253-7. PMID: 15916806.
      View in: PubMed
    194. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps T, Negrini M, Croce CM. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005 Oct 27; 353(17):1793-801. PMID: 16251535.
      View in: PubMed
    195. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps T, Rai K. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006 Feb 01; 107(3):859-61. PMID: 16223776.
      View in: PubMed
    196. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps T, Negrini M, Croce CM. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005 Sep 27; 102(39):13944-9. PMID: 16166262; PMCID: PMC1236577.
    197. Wierda WG, Kipps T, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6325-32. PMID: 16155015.
      View in: PubMed
    198. Messmer D, Kipps T. Treatment of solid tumors with immunotoxins. Breast Cancer Res. 2005; 7(5):184-6. PMID: 16168135; PMCID: PMC1242142.
    199. Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, Kipps T. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood. 2005 Oct 01; 106(7):2506-12. PMID: 15972449; PMCID: PMC1895276.
    200. Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, Nefzi A, Reed JC, Pinilla C, Kipps T. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood. 2005 Sep 01; 106(5):1742-8. PMID: 15914559; PMCID: PMC1895220.
    201. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps T, Burger JA. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005 Sep 01; 106(5):1824-30. PMID: 15905192.
      View in: PubMed
    202. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC, Zvaifler NJ, Kipps T. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005 Aug 01; 106(3):1012-20. PMID: 15860672; PMCID: PMC1895149.
    203. Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med. 2005 Apr 21; 352(16):1667-76. PMID: 15843669.
      View in: PubMed
    204. Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, Rassenti L, Kipps T, Grever MR, Byrd JC, Plass C. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 10; 23(17):3877-85. PMID: 15809452.
      View in: PubMed
    205. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, Kipps T. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol. 2005 Jan 15; 174(2):864-70. PMID: 15634908.
      View in: PubMed
    206. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, Weiss A, Kipps T. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood. 2005 Mar 01; 105(5):2036-41. PMID: 15514014.
      View in: PubMed
    207. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps T, Kantarjian HM, Keating M. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 01; 101(5):999-1008. PMID: 15329909.
      View in: PubMed
    208. Dicker F, Kater AP, Fukuda T, Kipps T. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood. 2005 Apr 15; 105(8):3193-8. PMID: 15339846.
      View in: PubMed
    209. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps T. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004 Aug 26; 351(9):893-901. PMID: 15329427.
      View in: PubMed
    210. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps T, Bullrich F, Negrini M, Croce CM. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004 Aug 10; 101(32):11755-60. PMID: 15284443; PMCID: PMC511048.
    211. Widhopf GF, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps T. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004 Oct 15; 104(8):2499-504. PMID: 15217828.
      View in: PubMed
    212. Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zhai D, Kipps T, Reed JC, Pellecchia M. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol. 2004 Mar; 11(3):389-95. PMID: 15123268.
      View in: PubMed
    213. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps T, Corr M, Carson DA. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):3118-23. PMID: 14973184; PMCID: PMC365753.
    214. Widhopf GF, Brinson DC, Kipps T, Tighe H. Transgenic expression of a human polyreactive Ig expressed in chronic lymphocytic leukemia generates memory-type B cells that respond to nonspecific immune activation. J Immunol. 2004 Feb 15; 172(4):2092-9. PMID: 14764674.
      View in: PubMed
    215. Pedersen IM, Zapata JM, Samuel T, Scott FL, Salvesen GS, Honda T, Gribble GW, Suh N, Sporn MB, Kipps T, Reed JC. Retraction: The triterpenoid CDDO-Imidazolide induces apoptosis and enhances fludarabine-induced apoptosis of CLL B-cells. Blood. 2004 Aug 15; 104(4):932. PMID: 14739219.
      View in: PubMed
    216. Burger M, Glodek A, Hartmann T, Schmitt-Gräff A, Silberstein LE, Fujii N, Kipps T, Burger JA. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003 Nov 06; 22(50):8093-101. PMID: 14603250.
      View in: PubMed
    217. Rieger R, Kipps T. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res. 2003 Jul 15; 63(14):4128-35. PMID: 12874017.
      View in: PubMed
    218. Kipps T. Immunobiology of chronic lymphocytic leukemia. Curr Opin Hematol. 2003 Jul; 10(4):312-8. PMID: 12799538.
      View in: PubMed
    219. Wu CC, Castro JE, Motta M, Cottam HB, Kyburz D, Kipps T, Corr M, Carson DA. Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells. Hum Gene Ther. 2003 Jun 10; 14(9):849-60. PMID: 12828856.
      View in: PubMed
    220. Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps T, Frank DA. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res. 2003 Jun; 9(6):2166-72. PMID: 12796382.
      View in: PubMed
    221. Greaves AW, Payne PR, Rassenti L, Kipps T. CRC Tissue Core Management System (TCMS): integration of basic science and clinical data for translational research. AMIA Annu Symp Proc. 2003; 853. PMID: 14728358; PMCID: PMC1480018.
    222. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps T. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003; 153-75. PMID: 14633781.
      View in: PubMed
    223. Payne PR, Greaves AW, Kipps T. CRC Clinical Trials Management System (CTMS): an integrated information management solution for collaborative clinical research. AMIA Annu Symp Proc. 2003; 967. PMID: 14728471; PMCID: PMC1480351.
    224. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Nov 26; 99(24):15524-9. PMID: 12434020; PMCID: PMC137750.
    225. Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps T, Reed JC. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood. 2002 Oct 15; 100(8):2965-72. PMID: 12351409.
      View in: PubMed
    226. Tolba KA, Bowers WJ, Eling DJ, Casey AE, Kipps T, Federoff HJ, Rosenblatt JD. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. Mol Ther. 2002 Oct; 6(4):455-63. PMID: 12377186.
      View in: PubMed
    227. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N, Kipps T, Choi YS, Bennett F, Reed JC. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood. 2002 Sep 01; 100(5):1795-801. PMID: 12176902.
      View in: PubMed
    228. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps T. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002 Dec 15; 100(13):4609-14. PMID: 12393534.
      View in: PubMed
    229. Kipps T. Immune and cell therapy of hematologic malignancies. Int J Hematol. 2002 Aug; 76 Suppl 1:269-73. PMID: 12430862.
      View in: PubMed
    230. Bashey A, Cantwell MJ, Kipps T. Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. Br J Haematol. 2002 Aug; 118(2):506-13. PMID: 12139739.
      View in: PubMed
    231. Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC, Kipps T. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Mar 19; 99(6):3854-9. PMID: 11891278; PMCID: PMC122613.
    232. Burger JA, Kipps T. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002 Mar; 43(3):461-6. PMID: 12002747.
      View in: PubMed
    233. Tsukada N, Burger JA, Zvaifler NJ, Kipps T. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002 Feb 01; 99(3):1030-7. PMID: 11807009.
      View in: PubMed
    234. Kipps T. Advances in classification and therapy of indolent B-cell malignancies. Semin Oncol. 2002 Feb; 29(1S2):98-104. PMID: 28140099.
      View in: PubMed
    235. Kipps T. Advances in classification and therapy of indolent B-cell malignancies. Semin Oncol. 2002 Feb; 29(1 Suppl 2):98-104. PMID: 11842396.
      View in: PubMed
    236. Zhong RK, Rassenti LZ, Kipps T, Chen J, Law P, Yu JF, Ball ED. Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia. Biol Blood Marrow Transplant. 2002; 8(10):557-68. PMID: 12434951.
      View in: PubMed